Acadia Pharmaceuticals 2024 Annual Report

Acadia Pharmaceuticals reported record 2024 revenues of $957.8 million, up 32% year-over-year, driven by strong performance of NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome. The company strengthened its executive leadership team and outlined a long-term growth strategy focused on its neuroscience and neuro-rare disease franchises with plans to expand globally.